AsCas12a-mediated NHEJ is also applied for SCD and β-thalassemia therapy by targeting the BCL11A or HBG-binding site, with high editing efficiency and HbF induction [133]. The gene discussed is BCL11A; the disease is Schnyder corneal dystrophy.